Avacta strengthens cancer treatment story with clinical advances - Share Talk

Avacta strengthens cancer treatment story with clinical advances

Avacta Group plc has reported significant progress across its pre|CISION oncology platform in its unaudited preliminary results for the year ended December 31, 2025, as the company advances multiple cancer therapies through clinical development.

The biotechnology group said it now has two programmes in clinical trials, including continued progress with AVA6000 and the advancement of AVA6103 into Phase 1 patient treatment.

Avacta highlighted encouraging efficacy and safety data from AVA6000, which forms part of the company’s tumour-targeted chemotherapy platform designed to reduce systemic toxicity while improving drug delivery directly to cancer tissue.

Financially, the company strengthened its balance sheet through multiple fundraisings, securing £22.5 million in new equity during 2025 followed by an additional £10 million financing completed in March 2026.

Management said the funding extends the group’s cash runway into the first quarter of 2027.

At the end of 2025, Avacta held cash and short-term deposits of £16.9 million.

The group reported a loss before tax from continuing operations of £36.84 million for the year, compared with a loss of £28.98 million in the previous year, reflecting continued investment into clinical development and research activities.

Avacta also confirmed completion of the disposal of its diagnostics businesses, marking a further step in its transition towards becoming a focused oncology therapeutics company.

Christina Coughlin said Avacta Group plc has made significant progress in strengthening its position as a focused oncology therapeutics business centred around its proprietary pre|CISION platform.

Coughlin highlighted that the company already has two programmes in clinical development, which she described as ahead of the industry norm for companies at a similar stage.

She said Avacta believes its pre|CISION technology offers a unique advantage by enabling cancer therapies to be delivered directly to tumours at effective concentrations while avoiding the severe toxic side effects often associated with conventional chemotherapy treatments.

The CEO also pointed to the company’s expanding intellectual property portfolio, which she said is attracting increasing interest from multiple parties regarding potential commercial partnerships and licensing opportunities.

According to Coughlin, these agreements could both generate future revenue and expand the potential applications of the company’s technology platform.

She added that Avacta’s financial position has been significantly strengthened following £32.5 million of fundraising over the past 18 months, providing sufficient funding into early Q1 2027 and through several anticipated clinical and commercial milestones.

Coughlin described the coming period as potentially transformative both for the company and for patients targeted by its oncology pipeline.

For further information from Avacta, please contact:

Avacta Group plc

Christina Coughlin, Chief Executive Officer

https://avacta.com/

via Cohesion Bureau


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned